on Gimv (EBR:GIMB)
Gimv Invests in Kivu Bioscience's $92M Series A Funding
Gimv has participated in a $92 million Series A funding round for Kivu Bioscience, a San Francisco-based biotech firm specializing in next-generation antibody-drug conjugates (ADCs) for oncology. The round was led by Novo Holdings, with contributions from Red Tree, HealthCap, BioGeneration Ventures, Merck Ventures, and Brabantse Ontwikkelings Maatschappij (BOM).
This funding aims to support clinical advances in ADC programs, utilizing Synaffix's platform to minimize off-target toxicity and enhance efficacy. Kivu's approach addresses key limitations of existing treatments by engineering stable ADCs, potentially reducing side effects and expanding therapeutic windows.
Gimv's investment aligns with its strategy in Life Sciences, seeking innovative solutions for cancer treatment. Kivu's pipeline, set to enter Phase 1 trials in 2025, shows promise for treating solid tumors more effectively.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Gimv news